Enzyme News and Research

RSS

Human Genome Sciences can begin cardiovascular disease research

Human Genome Sciences, Inc.announced today that it has received a clinical development milestone payment from its partner, GlaxoSmithKline, related to the initiation of Phase 1 clinical trials of 677116 for the treatment of cardiovascular disease. 677116 is a small-molecule inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme associated with the formation of atherosclerotic plaques.

30 Mar 2004

Enzyme called COX-2 may promote the development of ovarian tumors

Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.

29 Mar 2004

Snake venom launders out all stains

Purveyors of snake oil and its mythical powers may not have had it all wrong, if preliminary findings with the Florida cottonmouth, bloodstains and a washing machine stay on target. An enzyme extracted from the viper's venom appears to help launder out notoriously stubborn blood spots on clothing.

29 Mar 2004

Halting the development of certain pancreatic, ovarian, colon and lung cancers may be possible with new therapy

By investigating a single molecule that influences cell growth, a research group in the Purdue Cancer Center, including Brian S. Henriksen, has gained new insight into the chain of events that make some cancer cells divide uncontrollably, insight that may eventually lead to a way to break that chain, stopping cancer in its tracks. The molecule, known as Icmt, has a critical role in the development of Ras, an ordinarily beneficial protein that tells a cell to divide. The research group has determined how to inhibit Icmt's influence on Ras, without which the protein cannot develop effectively into an instigator of cell growth.

28 Mar 2004

p53 protein peptide stops cancer in its tracks

Researchers have dreamed of thwarting cancer by using proteins that halt cell growth and kill the tumor. In theory, the approach should work. In practice, however, scientists have not had an easy time of getting tumor suppressor proteins into cells where they can block growth effectively.

26 Mar 2004

A common antibiotic used to treat arthritis and acne shows promise for limiting the severity of spinal cord and brain injuries

When a fall, car crash, bullet, or knife crushes or cuts a spinal cord, the injury does not stop there. Rather, tissues continue to discharge toxic chemicals for hours, even days and weeks. These chemicals kill and disable nerve cells some distance away from the core injury, compounding the damage and making rehabilitation more difficult or impossible.

26 Mar 2004

Tiny Ribozyme package could be future treatment of Hepatitis B virus

Penn State College of Medicine researchers have developed a tiny package that searches for and destroys up to 80 percent of hepatitis B virus in the livers of mice.

22 Mar 2004

Enzyme Acetylcholinesterase (AChE), New Approach to Drug Design

French and American researchers have developed a unique approach to drug design where an important neuron-signaling enzyme called acetylcholinesterase (AChE) acts as a microscopic vessel filled with reactant chemicals, to create its own, tailored therapeutic agent.

22 Mar 2004

DNA repair enzymes to fight cancer

The body has a set of DNA repair enzymes that clean up damage to the genome, to reduce potential problems. Many commonly used cancer chemotherapies work by alkylating DNA. However, the DNA repair enzymes are just as capable of repairing this alkylation as if it were damage from any other source, and so they act to overcome the effects of the therapy, reducing its effectiveness.

22 Mar 2004

Pfizer breast cancer drug looks to be best in field

A breast cancer drug made by Pfizer Inc. increased survival rates by 63 percent compared with the standard therapy tamoxifen, researchers said on Wednesday. The clinical trial strengthens the case for administering the newer drug, exemestane, as a first option. A study published last week showed that women recovering from breast cancer lowered their chance of developing another tumor by 32 percent if they switched to exemestane after two or three years of tamoxifen treatment.

22 Mar 2004

AMT Obtains Orphan Drug Designation for Its LPL Gene Therapy Product

AMT today announced that its adeno-associated viral vector (AAV) expressing lipoprotein lipase (LPL) product has been designated as an orphan medicinal product for the treatment of LPL deficiency by the European Commission. This decision follows a positive recommendation by the European Agency for the Evaluation of Medicinal Products.

22 Mar 2004

Research suggests the orlistat drug could be used to fight cancer and obesity

The Burnham Institute’s Jeffrey Smith, Ph.D., has discovered that orlistat, commonly prescribed as an anti-obesity drug, has a positive side-effect: it inhibits cancer growth. Dr. Smith made this discovery using an activity-based proteomics screening technique developed in his laboratory that makes it possible to identify active targets and simultaneously screen for their inhibitors.

22 Mar 2004

Lupus Discovery May Lead To Improved Drugs

In an important development in the treatment of lupus as well as certain cancers, scientists at the Feinberg School of Medicine at Northwestern University have discovered how autoimmune lupus T cells stave off programmed cell death and drive production of autoantibodies directed against the body’s own DNA.

22 Mar 2004

New therapies that may treat cancers

Scientists at the Johns Hopkins Kimmel Cancer Center and Howard Hughes Medical Institute have found mutations in a gene linked to the progression of colon and other cancers. The research findings, may lead to new therapies and diagnostic tests that target this gene.

22 Mar 2004

Obesity Drug Inhibits Prostate Tumor Growth

The Burnham Institute's Jeffrey Smith, Ph.D. has discovered that orlistat, commonly prescribed as an anti-obesity drug, has a positive side-effect: it inhibits cancer growth. Dr. Smith made this discovery using an activity-based proteomics screening technique developed in his laboratory that makes it possible to identify active targets and simultaneously screen for their inhibitors.

22 Mar 2004